11.21-07

PTO/SB/21 (10-07)
Approved for use through 10/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Control number.			
	Application Number	10/672,069-Conf. #4721	
TRANSMITTAL FORM	Filing Date	September 25, 2003	
	First Named Inventor	Tariq M. RANA	
	Art Unit	1635	
(to be used for all correspondence after initial filing)	Examiner Name	K. Chong	
Total Number of Pages in This Submission	Attorney Docket Number	UMY-062	

			
ENCLOSURES (Check all that apply)			
Fee Transmittal Form	Drawing(s)	After Allowance Communication to TC	
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences	
Amendment/Reply	Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
After Final	Petition to Convert to a Provisional Application	Proprietary Information	
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Addres	Status Letter	
Extension of Time Request	Terminal Disclaimer	X Other Enclosure(s) (please Identify below):	
Express Abandonment Request	Request for Refund	Return Receipt Postcard PTO form SB/08	
X Information Disclosure Statement	CD, Number of CD(s)	Certificate of Mailing Copies of Four (4) References	
Certified Copy of Priority Document(s)			
Reply to Missing Parts/ Incomplete Application	Remarks	(4) (4) (4) (4) (4) (4) (4) (4) (4) (4)	
Reply to Missing Parts under 37 CFR 1.52 or 1.53			
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	•		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name LAHIVE & COCKFELD, LAP			
Signature			
Printed name Debra J. Milasincic, Esq.			
Date November 20, 2007	Reg. N	lo. 46,931	

Docket No.: UMY-062 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Tariq M. Rana

Application No.: 10/672,069

Confirmation No.: 4721

Filed: September 25, 2003

Art Unit: 1635

For:

IN VIVO GENE SILENCING BY

CHEMICALLY MODIFIED AND STABLE

siRNA

Examiner: K. Chong

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

Dear Sir:

In accordance with 37 CFR 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicants have become aware of the following documents, cited in a European Search Report issued September 12, 2007, during the prosecution of Application No. 03774498.4 - 2403, which corresponds to the above referenced application, and in accordance with 37 CFR 1.97(c) and (e)(1) or (b)(3), hereby submit these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of the Search Report and of each document required under 37 CFR 1.98(a)(2) cited thereon are enclosed as well.

Please note that Applicants' attorney does not include in this Supplemental Information Disclosure Statement reference WO02/44321, cited in an Office Action dated February 12, 2007, Chiu, "RNAi in human cells...," and Chiu, "siRNA function in...," cited in an

Application No.: 10/672,069 Docket No.: UMY-062

Information Disclosure Statement dated February 24, 2006, WO02/16620 and WO04/014933, cited in an Information Disclosure Statement dated August 13, 2007 and Parrish, "Functional anatomy...," cited in an Office Action dated October 24, 2005.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

I hereby certify, pursuant to 37 CFR 1.97(e)(1), that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. UMY-062.

Dated: November 20, 2007

DJM/JAM/mch

Respectfully submitted,

Qebra J. Milasincic, Esq. Registration No.: 46,931

LAHIVE & COCKFIELD, LLP

One Post Office Square

Boston, Massachusetts 02109-2127

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant


Application No. (if known): 10/672,069

Attorney Docket No.: UMY-062

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EM 066424535 US in an envelope addressed to:

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450



Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Return Receipt Postcard Transmittal (1 page)

Supplemental Information Disclosure Statement (2 pages)

PTO form SB/08 (4 Referencse) (1 page)

Copies of Four (4) References